Covered recipient · General Payments record
JOHN G BIGGS
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,999.68
- Reported across 127 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $297.53 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $80.69 | 5 |
| ABBVIE INC. | $77.47 | 4 |
| Amneal Pharmaceuticals LLC | $45.20 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.68 | 1 |
| Lilly USA, LLC | $29.97 | 2 |
| Amgen Inc. | $16.46 | 1 |
| GlaxoSmithKline, LLC. | $15.06 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.55 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103326564 | CMS |
| ABBVIE INC. | $18.55 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103326566 | CMS |
| ABBVIE INC. | $18.73 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103326568 | CMS |
| ABBVIE INC. | $21.64 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103326570 | CMS |
| Amgen Inc. | $16.46 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111530274 | CMS |
| Amneal Pharmaceuticals LLC | $23.77 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139180597 | CMS |
| Amneal Pharmaceuticals LLC | $21.43 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139180599 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.68 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118266417 | CMS |
| GlaxoSmithKline, LLC. | $15.06 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115921088 | CMS |
| Lilly USA, LLC | $15.24 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135071397 | CMS |
| Lilly USA, LLC | $14.73 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135033138 | CMS |
| Novo Nordisk Inc | $17.35 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096922848 | CMS |
| Novo Nordisk Inc | $13.80 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096708117 | CMS |
| Novo Nordisk Inc | $14.41 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097374623 | CMS |
| Novo Nordisk Inc | $20.26 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097008369 | CMS |
| Novo Nordisk Inc | $14.87 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097195394 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.